Adaptimmune Therapeutics plc [NASDAQ:ADAP]: Analyst Rating and Earnings
Stock traders often pay close attention what Wall Street analysts have to say about a potential investment. For Adaptimmune Therapeutics plc [ADAP], the latest consensus recommendation available followed its financial results for the fiscal quarter ending in December. On average, stock market experts give ADAP an Outperform rating. The average 12-month price forecast for this stock is $14.00, with the high estimate being $18.00, the low estimate being $7.00 and the median estimate amounting to $16.00. This is compared to its latest closing price of $5.80.
Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Adaptimmune Therapeutics plc [ADAP] is sitting at 2.11. This is compared to 1 month ago, when its average rating was 2.00.
For the quarter ending in Sep-18 Adaptimmune Therapeutics plc [ADAP] generated $0.04 billion in sales. That’s 23.51% higher than the average estimate of $0.03 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.
Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Thu 21 Mar (In 70 Days).
Fundamental Analysis of Adaptimmune Therapeutics plc [ADAP]
Now let’s turn to look at profitability: with a current Operating Margin for Adaptimmune Therapeutics plc [ADAP] sitting at -238.31. These metrics indicate that this company is not generating as much profit, after accounting for expenses, compared to its market peers.
This company’s Return on Total Capital is -49.14, and its Return on Invested Capital has reached -40.00%. Its Return on Equity is -38.23, and its Return on Assets is -27.36. These metrics suggest that this Adaptimmune Therapeutics plc does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.
What about valuation? This company’s Enterprise Value to EBITDA is -4.55. The Enterprise Value to Sales for this firm is now 6.25. Adaptimmune Therapeutics plc [ADAP] has a Price to Book Ratio of 3.08.
Shifting the focus to workforce efficiency, Adaptimmune Therapeutics plc [ADAP] earns $103,069 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 5.81 and its Total Asset Turnover is 0.15. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 3.10 and its Current Ratio is 3.10. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.
Let’s now turn our attention to trading performance: Adaptimmune Therapeutics plc [ADAP] has 101.28M shares outstanding, amounting to a total market cap of $590.46M. Its stock price has been found in the range of 3.60 to 14.63. At its current price, it has moved by -60.14% from its 52-week high, and it has moved 61.94% from its 52-week low.
This stock’s Beta value is currently 1.75, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 55.41. This RSI score is good, suggesting this stock is neither overbought or oversold.
Conclusion: Is Adaptimmune Therapeutics plc [ADAP] a Reliable Buy?
Shares of Adaptimmune Therapeutics plc [ADAP], on the whole, present investors with both positive and negative signals. Wall Street analysts have mixed reviews when it comes to the 12-month price outlook, and this company’s financials show a combination of strengths and weaknesses. Based on the price performance, this investment is somewhat risky while presenting reasonable potential for ROI.